MetaCap

Bicara Therapeutics (BCAX) vs Climb Bio (CLYM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Climb Bio (CLYM) has outperformed Bicara Therapeutics (BCAX) over the past year, gaining 440.6% versus a loss of 53.2%. Bicara Therapeutics is the larger company by market cap ($560.3 million vs $539.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BCAX-53.22%CLYM+440.59%
+1000%+447%-106%
Nov 21, 20251 yearNov 20, 2026
BCAX-63.95%CLYM+8.63%
+114%+9%-96%
Sep 9, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BCAX versus CLYM key metrics
MetricBCAXCLYM
Share price$8.44$9.19
Market cap$560.31M$539.80M
1-day change-7.46%-0.97%
YTD return-49.85%+129.75%
1-year return-53.22%+440.59%
5-year return—-33.21%
EPS (TTM)$-3.46$-0.81
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-137.95M$-59.85M
52-week high$30.99$18.33
52-week low$7.87$1.64
Distance from 52-week high-72.77%-49.86%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+281.16%+209.03%
Average volume1.20M1.38M
Shares outstanding66.39M58.74M
Employees10328
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CLYM has outperformed BCAX by 493.8 percentage points over the past year.

About Bicara Therapeutics

BCAX stock →

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 103 employees

About Climb Bio

CLYM stock →

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees

BCAX vs CLYM FAQ

Which is bigger, Bicara Therapeutics or Climb Bio?

Bicara Therapeutics (BCAX) is larger, with a market capitalization of $560.31M compared with $539.80M for Climb Bio (CLYM).

Which stock has performed better over the past year, BCAX or CLYM?

CLYM returned +440.59% over the past 12 months, compared with -53.22% for BCAX (price return, excluding dividends). Past performance does not predict future results.

Are Bicara Therapeutics and Climb Bio in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons